Prevention of cervical cancer through two HPV-based screen-and-treat implementation models in Malawi: protocol for a cluster randomized feasibility trial

Jennifer H Tang, Jennifer S Smith, Shannon McGue, Luis Gadama, Victor Mwapasa, Effie Chipeta, Jobiba Chinkhumba, Erik Schouten, Bagrey Ngwira, Ruanne Barnabas, Mitch Matoga, Maganizo Chagomerana, Lameck Chinula, Jennifer H Tang, Jennifer S Smith, Shannon McGue, Luis Gadama, Victor Mwapasa, Effie Chipeta, Jobiba Chinkhumba, Erik Schouten, Bagrey Ngwira, Ruanne Barnabas, Mitch Matoga, Maganizo Chagomerana, Lameck Chinula

Abstract

Background: Cervical cancer is the leading cause of cancer incidence and mortality among Malawian women, despite being a largely preventable disease. Implementing a cervical cancer screening and preventive treatment (CCSPT) program that utilizes rapid human papillomavirus (HPV) testing on self-collected cervicovaginal samples for screening and thermal ablation for treatment may achieve greater coverage than current programs that use visual inspection with acetic acid (VIA) for screening and cryotherapy for treatment. Furthermore, self-sampling creates the opportunity for community-based screening to increase uptake in populations with low screening rates. Malawi's public health system utilizes regularly scheduled outreach and village-based clinics to provide routine health services like family planning. Cancer screening is not yet included in these community services. Incorporating self-sampled HPV testing into national policy could address cervical cancer screening barriers in Malawi, though at present the effectiveness, acceptability, appropriateness, feasibility, and cost-effectiveness still need to be demonstrated.

Methods: We designed a cluster randomized feasibility trial to determine the effectiveness, acceptability, appropriateness, feasibility, and budget impact of two models for integrating a HPV-based CCSPT program into family planning (FP) services in Malawi: model 1 involves only clinic-based self-sampled HPV testing, whereas model 2 includes both clinic-based and community-based self-sampled HPV testing. Our algorithm involves self-collection of samples for HPV GeneXpert® testing, visual inspection with acetic acid for HPV-positive women to determine ablative treatment eligibility, and same-day thermal ablation for treatment-eligible women. Interventions will be implemented at 14 selected facilities. Our primary outcome will be the uptake of cervical cancer screening and family planning services during the 18 months of implementation, which will be measured through an Endline Household Survey. We will also conduct mixed methods assessments to understand the acceptability, appropriateness, and feasibility of the interventions, and a cost analysis to assess budget impact.

Discussion: Our trial will provide in-depth information on the implementation of clinic-only and clinic-and-community models for integrating self-sampled HPV testing CCSPT with FP services in Malawi. Findings will provide valuable insight for policymakers and implementers in Malawi and other resource-limited settings with high cervical cancer burden.

Trial registration: ClinicalTrials.gov identifier: NCT04286243 . Registered on February 26, 2020.

Keywords: Cervical cancer; Community; Family planning; HPV testing; Implementation; Malawi; Screening; Self-sampling; Sub-Saharan Africa; Thermal ablation.

Conflict of interest statement

The authors declare that they have no competing interests. JSS has received research grants and consultancies from BD Diagnostics and Hologic, and supply donations from Rovers and Arbor Vita over the past 5 years.

Figures

Fig. 1
Fig. 1
Study phases, with activities listed for each phase. Italicized portion indicates site selection and implementation of the two models under the appropriate phases. *Due to constraints on community services offered at two matched facilities, these facilities were both assigned to model 1 and dropped from randomization scheme. Thus, 9 facilities will implement model 1 and 7 will implement model 2
Fig. 2
Fig. 2
Patient flow for screening and treatment. Blue boxes and darker arrows indicate the community components that will only be present in model 2. *Note that result return will be delayed for community-screened women; same-day results will only be possible for women screened at facilities. HSA, health surveillance assistant

References

    1. International Agency for Cancer Research (FR). Malawi fact sheet, 2019 [Internet]. World Health Organization: 2019 May. . Accessed 13 May 2020.
    1. Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):E191–E203. doi: 10.1016/S2214-109X(19)30482-6.
    1. Msyamboza KP, Phiri T, Sichali W, Kwenda W, Kachale F. Cervical cancer screening uptake and challenges in Malawi from 2011 to 2015: retrospective cohort study. BMC Public Health. 2016;16(1):806. doi: 10.1186/s12889-016-3530-y.
    1. World Health Organization (CH). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. South Africa: WHO Africa; 2013. 40p. . Accessed 13 May 2020
    1. Mustafa RA, Santesso N, Khatib R, Mustafa AA, Wiercioch W, Kehar R, Gandhi S, Chen Y, Cheung A, Hopkins J, Ma B, Lloyd N, Wu D, Broutet N, Schünemann HJ. Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. Int J Gynaecol Obstet. 2016;132(3):259–265. doi: 10.1016/j.ijgo.2015.07.024.
    1. Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, Cubie H, Moore C, Kleeman M, Austin J, Ashdown-Barr L, Hunt K, Cadman L. Performance of the Xpert HPV assay in women attending for cervical screening. Papillomavirus Res. 2015;1:32–37. doi: 10.1016/j.pvr.2015.05.002.
    1. Rosenbaum AJ, Gage JC, Alfaro KM, Ditzian LR, Maza M, Scarinci IC, Felix JC, Castle PE, Villalta S, Miranda E, Cremer ML. Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. Int J Gynaecol Obstet. 2014;126(2):156–160. doi: 10.1016/j.ijgo.2014.02.026.
    1. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob Health. 2019;4(3):e001351. doi: 10.1136/bmjgh-2018-001351.
    1. Lin C, Zeng X, Cui J, Liao G, Wu Z, Gao Q, et al. Stability study of cervical specimens collected by swab and stored dry followed by human papillomavirus DNA detection using the cobas 4800 test. J Clin Microbiol. 2017;55(6):568–573. doi: 10.1128/JCM.02025-16.
    1. Ejegod DM, Pedersen H, Alzua GP, Pedersen C, Bonde J. Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening. Papillomavirus Res. 2018;5:192–200. doi: 10.1016/j.pvr.2018.04.005.
    1. Randall TC, Sauvaget C, Muwonge R, Trimble EL, Jeronimo J. Worthy of further consideration: an updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019;118:81–91. doi: 10.1016/j.ypmed.2018.10.006.
    1. Pinder LF, Parham GP, Basu P, Muwonge R, Lucas E, Nyambe N, Sauvaget C, Mwanahamuntu MH, Sankaranarayanan R, Prendiville W. Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. Lancet Oncol. 2020;21(1):175–184. doi: 10.1016/S1470-2045(19)30635-7.
    1. Malawi Ministry of Health . National Cervical Cancer Prevention Program Strategy. Lilongwe, Malawi: Ministry of Health; 2016. p. 57.
    1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, volume VIII. Lyon, France: International Agency for Research on Cancer; 2004. p. 773.
    1. High-Impact Practices in Family Planning (HIPs) Community health workers: bringing family planning services to where people live and work. Washington (DC): USAID; 2015.
    1. National Statistical Office (NSO) and ICF . Malawi demographic and health survey 2015-16. Zomba, Malawi, and Rockville, Maryland, USA: NSO and ICF; 2017. p. 658.
    1. Lemani C, Tang JH, Kopp D, Phiri B, Kumvula C, Chikosi L, Mwale M, Rosenberg NE. Contraceptive uptake after training community health workers in couples counseling: a cluster randomized trial. PLoS One. 2017;12(4):e0175879. doi: 10.1371/journal.pone.0175879.
    1. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, Barletta P, Laudi R, Orellana L, EMA Study team Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (The EMA Study): a population-based cluster-randomised trial. Lancet Glob Health. 2015;3(2):e85–e94. doi: 10.1016/S2214-109X(14)70354-7.
    1. Moses E, Pedersen HN, Mitchell SM, Sekikubo M, Mwesigwa D, Singer J, Biryabarema C, Byamugisha JK, Money DM, Ogilvie GS. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial. Trop Med Int Health. 2015;20(10):1355–1367. doi: 10.1111/tmi.12549.
    1. Rohner E, Butikofer L, Schmidlin L, Sengavi M, Maskew M, Giddy J, et al. Cervical cancer risk in women living with HIV across four continents: a multicohort study. Int J Cancer. 2020;146(3):601–609. doi: 10.1002/ijc.32260.
    1. The World Bank. Malawi [Internet]. 2020. . Accessed 13 May 2020.
    1. Africa Health Workforce Observatory. Human resources for health country profile, Malawi. 2009 Oct. 55p. . Accessed 13 May 2020.
    1. Smith S, Deveridge A, Berman J, Negan J, Mwambene N, Chingaipe E, et al. Task-shifting and prioritization: a situational analysis examining the role and experiences of community health workers in Malawi. Hum Resour Health. 2014;12(1):24. doi: 10.1186/1478-4491-12-24.
    1. Mwapasa V, Joseph J, Tchereni T, Jousset A, Gunda A. Impact of mother-infant pair clinics and short-text messaging service (SMS) reminders on retention of HIV-infected women and HIV-exposed infants in eMTCT care in Malawi: a cluster randomized trial. J Acquir Immune Defic Syndr. 2017;75(Suppl 2):S123–S131. doi: 10.1097/QAI.0000000000001340.
    1. Dovel K, Shaba F, Nyirenda M, Offorjebe OA, Balakasi K, Phiri K, Nichols B, Tseng CH, Bardon A, Ngona K, Hoffman R. Evaluating the integration of HIV self-testing into low-resource health systems: study protocol for a cluster-randomized control trial from EQUIP innovations. Trials. 2018;19(1):498. doi: 10.1186/s13063-018-2878-y.
    1. Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, et al. Performance of a cartridge-based assay for detection of clinically significant human papillomavirus (HPV) infection: lessons from VALGENT (Validation of HPV Genotyping Tests) J Clin Microbiol. 2016;54(9):2337–2342. doi: 10.1128/JCM.00897-16.
    1. Cubie HA, Morton D, Kawonga E, Mautanga M, Mwenitete I, Teakle N, Ngwira B, Walker H, Walker G, Kafwafwa S, Kabota B, ter Haar R, Campbell C. HPV prevalence in women attending cervical screening in rural Malawi using the cartridge-based Xpert® HPV assay. J Clin Virol. 2017;87:1–4. doi: 10.1016/j.jcv.2016.11.014.
    1. Zeger SL, Liang K, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049–1060. doi: 10.2307/2531734.
    1. Li P, Redden DT. Small sample performance of bias-corrected sandwich estimators for cluster-randomized trials with binary outcomes. Stat Med. 2015;34(2):281–296. doi: 10.1002/sim.6344.
    1. May CR, Cummings A, Girling M, Bracher M, Mair FS, May CM, Murray E, Myall M, Rapley T, Finch T. Using Normalization Process Theory in feasibility studies and process evaluations of complex healthcare interventions: a systematic review. Implement Sci. 2018;13(1):80. doi: 10.1186/s13012-018-0758-1.
    1. Smith JA, Sharma M, Levin C, Baeten JM, van Rooyen H, Celum C, Hallett TB, Barnabas RV. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV. 2015;2(4):e159–e168. doi: 10.1016/S2352-3018(15)00016-8.
    1. Golovaty I, Sharma M, Van Heerden A, van Rooyen H, Baeten JM, Celum C, et al. Cost of integrating non-communicable disease screening into home-based HIV testing and counseling in South Africa. J Acquir Immune Defic Syndr. 2018;78(5):522–526. doi: 10.1097/QAI.0000000000001713.
    1. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006;3(5):e138. doi: 10.1371/journal.pmed.0030138.
    1. Tan N, Sharma M, Winer R, Galloway D, Rees H, Barnabas RV. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa. Vaccine. 2018;36(32 Pt A):4830–4836. doi: 10.1016/j.vaccine.2018.02.023.
    1. Mezei AK, Pedersen HG, Sy S, Regan C, Mitchell-Foster SM, Byamugisha J, et al. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial. BMJ Open. 2018;8(6):e020484. doi: 10.1136/bmjopen-2017-020484.
    1. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016;2(1):64. doi: 10.1186/s40814-016-0105-8.

Source: PubMed

3
Sottoscrivi